Company Directory / biotech/health
Public · NASDAQ:GRCLFor profitbiotech/healthChina
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
- Founded
- 2017 9 years ago
- Staff
- 251-500 band, as listed
- Followers
- - on LinkedIn
- Funding
- $285M as listed, currency not stated
Set against six million companies
Size
251-500 people: larger than 92% of companies with a size listed
Age
9 years old.
Reach
Website ranked #5,013,965 in the world for traffic, about 2k visits a month.
What it does
BiotechnologyHealth CareMedical
Funding, as listed
$285M currency not stated
- Rounds4
- LatestPost ipo equity, Aug 2023
- Investors17, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Gracell Biotechnologies, field by field. Contact details are held but never shown.
The company
- Name
- Gracell Biotechnologies
- Type
- For profit
- Status
- Public · NASDAQ:GRCL
- Founded
- 2017
- Founders
- Wei William Cao
- Industry
- biotech/health
- Categories
- Biotechnology, Health Care, Medical
Where
- Country
- China
- Markets
- Asia-Pacific (APAC)
Size and reach
- Staff band
- 251-500
- Web traffic rank
- #5,013,965
- Monthly web visits
- 1,646
Funding, as listed
- Total
- 285,000,000 (currency not stated)
- Rounds
- 4
- Latest round
- Post ipo equity
- Latest round date
- Aug 2023
- Investors
- 17
- Lead investors
- 4
- Stock listing
- NASDAQ:GRCL
- Listing status
- public
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Gracell Biotechnologies may be growing as it has been acquired by AstraZeneca in a deal valued at $1.2 billion, which is a significant financial transaction indicating a valuation growth. The acquisition by a major pharmaceutical company suggests confidence in Gracell's potential and capabilities in the biotechnology and health care industry. Furthermore, the deal is part of AstraZeneca's strategy to further its cell therapy ambition across oncology and autoimmune diseases, which implies that Gracell's technologies are considered valuable assets in these therapeutic areas.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotech/health in China.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 38,667 companies in China and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.